Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

Area of Science:

• Biochemistry
• Immunology
• Oncology

Background:

• Ecto-5'-nucleotidase/CD73 is crucial for creating an immunosuppressive tumor microenvironment by generating adenosine.
• This adenosine-rich niche promotes tumor growth, angiogenesis, and immune evasion.

Discussion:

• Targeting CD73 can reverse the immunosuppressive effects within the tumor microenvironment.
• Modulating CD73 activity influences the behavior and phenotype of tumor-infiltrating T cells.

Key Insights:

• Inhibition of CD73 leads to a less immunosuppressive and potentially anti-angiogenic tumor milieu.
• CD73 targeting reshapes the immune cell landscape, enhancing anti-tumor T cell responses.

Outlook:

• CD73 monoclonal antibodies represent a promising therapeutic strategy for various cancers.
• Further research into CD73-targeted therapies could revolutionize antineoplastic treatment.